1. Signaling Pathways
  2. Antibody-drug Conjugate/ADC Related
  3. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148057
    TCO-PEG4-VC-PAB-MMAE
    99.30%
    TCO-PEG4-VC-PAB-MMAE is a agent-linker conjugate for ADC. TCO-PEG4-VC-PAB-MMAE contains a cleavable ADC linker (TCO-PEG4-VC-PA) and a potent tubulin inhibitor MMAE (HY-15162). TCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.
    TCO-PEG4-VC-PAB-MMAE
  • HY-148668
    MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan
    MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan is a agent-linker conjugates for ADC, consisting Exatecan (HY-13631). Exatecan is a DNA Topoisomerase I inhibitor (IC50=2.2 μM).
    MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan
  • HY-148426
    OSu-PEG4-VC-PAB-MMAE
    98.19%
    OSu-PEG4-VC-PAB-MMAE involves in GDP-FAmP4MMAE (Monomethylauristatin E) synthesis, which is for GDP label via site-specific conjugation.
    OSu-PEG4-VC-PAB-MMAE
  • HY-154915
    MC-EVCit-PAB-MMAE
    99.04%
    MC-EVCit-PAB-MMAE (Linker-Payload 11) is a drug-linker conjugates for ADC. MC-EVCit-PAB-MMAE contains the ADCs linker (MC-EVCit-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162).
    MC-EVCit-PAB-MMAE
  • HY-126681
    SC-VC-PAB-MMAE
    99.29%
    SC-VC-PAB-MMAE is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB.
    SC-VC-PAB-MMAE
  • HY-126494
    DM4-SMCC
    DM4-SMCC is a agent-linker conjugate for ADC with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker.
    DM4-SMCC
  • HY-132250
    MCC-DM1
    99.52%
    MCC-DM1 is a agent-Linker Conjugates for ADC such as Anti-CD22-MCC-DM1. MCC-DM1 can be detected in rat and human plasma, feces, and other tissues.
    MCC-DM1
  • HY-136288
    Azide-PEG4-VC-PAB-Doxorubicin
    98.47%
    Azide-PEG4-VC-PAB-Doxorubicin is a agent-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody agent conjugate (ADC). Azide-PEG4-VC-PAB-Doxorubicin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    Azide-PEG4-VC-PAB-Doxorubicin
  • HY-155870A
    DL-01 formic
    DL-01 formic is a drug-linker conjugates for ADC that can be used for the synthesis of ADCs.
    DL-01 formic
  • HY-153032
    Val-Ala-PAB-MMAE
    Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE. MMAE is an effective inhibitor of tubulin.
    Val-Ala-PAB-MMAE
  • HY-15575G
    VcMMAE (GMP)
    VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC.
    VcMMAE (GMP)
  • HY-130989
    SuO-Glu-Val-Cit-PAB-MMAE
    99.20%
    SuO-Glu-Val-Cit-PAB-MMAE (NHS-Glutarate-Val-Cit-PAB-MMAE) consists a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
    SuO-Glu-Val-Cit-PAB-MMAE
  • HY-128943
    MAC glucuronide phenol-linked SN-38
    98.49%
    MAC glucuronide phenol-linked SN-38 is a pH-susceptible lactone MAC glucuronide phenol-linked SN-38 (DNA topoisomerase I inhibitor) agent linker. MAC glucuronide phenol-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC50 values of 113 and 67 ng/mL, respectively.Albumin-coupled MAC glucosidol-linked SN-38 shows good stability in mouse plasma.
    MAC glucuronide phenol-linked SN-38
  • HY-133492
    DBCO-PEG4-MMAF
    99.31%
    DBCO-PEG4-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4. DBCO-PEG4-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-MMAF
  • HY-130812
    Gemcitabine-O-Si(di-iso)-O-Mc
    98.82%
    Gemcitabine-O-Si(di-iso)-O-Mc is a agent-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker.
    Gemcitabine-O-Si(di-iso)-O-Mc
  • HY-164239
    NH2-PEG3-VC-PAB-MMAE
    99.10%
    NH2-PEG3-VC-PAB-MMAE is a drug-linker conjugate for ADC, consisting of a cleavable ADC linker (NH2-PEG3-VC-PAB) and a potent tubulin inhibitor Monomethyl auristatin E (MMAE) (HY-15162). NH2-PEG3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
    NH2-PEG3-VC-PAB-MMAE
  • HY-153263
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthetic preparation of drug-linker conjugates for ADC. (Aminooxy)acetamide-Val-Cit-PAB-MMAE is conjugated to polyamide via oxime bond formation to form MMAE polyamide conjugate. Then MMAE polyamide conjugate can be conjugated to Trastuzumab, to make ADC.
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE
  • HY-156755
    Propargyl-PEG4-GGFG-DXd
    99.99%
    Propargyl-PEG4-GGFG-DXd is a drug-linker conjugate for ADC. Propargyl-PEG4-GGFG-DXd contains a ADC linker and a DNA topoisomerase I inhibitor DXd (HY-13631D).
    Propargyl-PEG4-GGFG-DXd
  • HY-111554
    AcLys-PABC-VC-Aur0101
    98.49%
    AcLys-PABC-VC-Aur0101 is a agent-linker conjugate for ADC (anti-CXCR4 ADC) with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the cleavable linker AcLys-PABC-VC.
    AcLys-PABC-VC-Aur0101
  • HY-141833
    Bi-Mc-VC-PAB-MMAE
    99.78%
    Bi-Mc-VC-PAB-MMAE consists ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Bi-Mc-VC-PAB-MMAE is a agent-linker conjugate for ADC.
    Bi-Mc-VC-PAB-MMAE

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.